The Effect of Anakinra on Paclitaxel-Induced Peripheral Neuropathic Pain in Rats

Kuyrukluyıldız, Ufuk; Küpeli, İlke; Bedir, Zehra; Özmen, Özgür; Önk, Didem; Mammadov, Renad; Süleyman, Halis

doi:10.5152/tjar.2016.02212

Cited by 17 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MtX caused oxidative stress by increasing MdA levels and decreasing tGsH levels in the small intestine tissue and confirmed histopatho-logical changes [2]. it has been also reported that MtX caused increased MdA and decreased tGsH levels in the other organs [13]. in the light of this knowledge, studies focus on antioxidants to reduce the side effects of MTX [8].…”

Section: Discussionmentioning

confidence: 58%

“…these studies showed that MtX causes both oxidative stress and inflammatory damage in the small intestine. it has been reported that anakinra inhibits the production of oxidant and proinflammatory IL-1β [13]. Nayki et al reported that anakinra at a dose of 100 mg/ kg inhibits the histopathological damage better than at a dose of 50 mg/kg and also makes better suppression of the oxidants production and IL-1β expression compared to at a dose of 50 mg/kg [15].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of anakinra on the small intestine mucositis induced by methotrexate in rats

et al. 2020

Self Cite

View full text Add to dashboard Cite

Intestinal mucositis is an important problem in the patients receiving cancer treatment. We aimed to investigate the effect of anakinra, which is a well known anti-oxidant and anti-inflammatory agent, on methotrexateinduced small intestine mucositis in rats. Forty rats were divided into 4 groups with 10 in each group. The healthy group (HG) and the methotrexate group (MTXG) were given distilled water, while the methotrexate + anakinra 50 (MTX+ANA50) and the methotrexate + anakinra 100 (MTX+ANA100) groups were intraperitoneally administered 50 and 100 mg/kg of anakinra. After one hour, the MTXG, MTX+ANA50 and MTX+ANA100 groups were given oral methotrexate at a dose of 5 mg/kg. This procedure was repeated once a day for 7 days. After the rats had been sacrificed, the small intestine tissue of rats were removed for the assesment of biochemical markers, histopathological evaluation and gene expression analyze. Statistical analyses of the data were performed using one-way ANOVA. Malondialdehyde (MDA), myeloperoxidase (MPO) and interleukin-6 (IL-6) levels were significantly higher, whereas total glutathione (tGSH) levels were significantly lower in MTXG (P<0.001) compared to other groups. MTX also increased IL-1β and TNF-α gene expression levels in MTXG (P<0.001). Inflammatory cell infiltration and damage to the villus were observed histopathologically in the MTXG group, whereas only mild inflammation was seen in the MTX+ANA100 group. A dose of 100 mg/kg of anakinra prevented the increase of the biochemical markers and gene expression levels better than a dose of 50 mg/kg. Intestinal mucositis caused by MTX may be preventible by co-administered anakinra.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Effects of anakinra on the small intestine mucositis induced by methotrexate in rats

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…rolipram mechanism of action is based on the modulation of the cyclic AmP (cAmP) levels involved in the neuropathic pain expansion [17]. In the terms of pro-inflammatory mechanism of neuropathic pain, inhibition of Il-1 and Il-6 signaling pathways with the usage of anakinra (Il-1 antagonist) or tocilizumab (Il-6 blocker) is proposed [13,18,19]. nociceptive pain originates from the activation of high-threshold afferents defined as nociceptors.…”

Section: Pain -Pathophysiologymentioning

confidence: 99%

Cancer pain as a meaningful aspect of the oncological treatment

et al. 2021

View full text Add to dashboard Cite

Introduction and objective: Pain is the most common and universal symptom among all patients with the oncological disease. Pain significantly reduces the quality of life, hinders decent functioning, and plays a significant role in the deterioration of the mental health of the patient and his close relatives. The study aimed to discuss the mainstreaming of effective pain treatment and to review various assessments and scales (including Brief Pain Inventory, Illness Perception Questionnaire and Numeric Rating Scale) concerning the psychological aspect of pain in selected neoplastic diseases.State of knowledge: We can distinguish various treatments for pain that can be divided into pharmacological and non-pharmacological methods. Latest studies revealed that pain treatment appears to be more and more meaningful. Various factors might influence pain perception and response to the applied treatment. Among all malignancies, special attention is paid to the pain issue in following cancers: colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, breast cancer and lung cancer, that were described in this paper.Conclusions: Effective pain relief presents a positive effect, both on the physical and mental state of the patient. It also helps to maintain calm mental health among relatives. Nowadays, integration of the best methods for pain relief that are characterized as humanitarian, easily accessible and effective, seems to be one of the biggest challenges for both oncological and palliative health workers.

show abstract

“…PACLI contributes to ROS formation (superoxide, hydroxyl radical, nitric oxide and hydrogen peroxide) through changes in neuronal mitochondria (swollen and vacuolated) that are involved in nerve injury‐induced and inflammatory pain through TRPA1 channels . The administration of PACLI also results in the production of interleukin‐1 beta (IL‐1β) and other proinflammatory cytokines and their release from microglia cells …”

Section: Chemotherapy‐induced Peripheral Neuropathy – Mechanisms Of Fmentioning

confidence: 99%

The use of antioxidant agents for chemotherapy‐induced peripheral neuropathy treatment in animal models

Carvalho

Silva

Carvalho

2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

SummaryAntineoplastic drugs such as cisplatin, oxaliplatin, paclitaxel and vincristin are widely used in the treatment of several solid and blood tumours. However, the severity of peripheral neuropathy caused by these agents can affect the patient's quality of life.The major symptoms of chemotherapy-induced peripheral neuropathy (CIPN) involve: sensory loss, paresthesia, dysesthaesia, numbness, tingling, temperature sensitivity, allodynia and hyperalgesia, in a "stocking and glove" distribution. Why many different chemotherapeutic agents result in similar neuropathy profiles is unclear. Many drug classes such as antidepressants, anticonvulsants, antispastic agents and others have been used in clinical practice, but there is no scientific evidence to prove their effectiveness. But drugs as the antioxidant have shown a protective effect against free radical damage. In order to find out a successful treatment for CIPN, animal studies (ie pharmacological and mechanical tests and histopathological immunohistochemical analyses) have been developed to try to determinate the action of the antioxidant agents. This review provides an overview of the major antioxidant agents recently investigated to treat CIPN and the animal models used for this purpose. K E Y W O R D Santineoplastic drugs, antioxidants, peripheral neuropathy

show abstract

The Effect of Anakinra on Paclitaxel-Induced Peripheral Neuropathic Pain in Rats

Cited by 17 publications

References 28 publications

Effects of anakinra on the small intestine mucositis induced by methotrexate in rats

Effects of anakinra on the small intestine mucositis induced by methotrexate in rats

Cancer pain as a meaningful aspect of the oncological treatment

The use of antioxidant agents for chemotherapy‐induced peripheral neuropathy treatment in animal models

Contact Info

Product

Resources

About